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Abstract
Background: Bladder cancer is the seventh-leading cause of cancer-related deaths in the US. Presenting signs
include hematuria and irritative voiding symptoms including dysuria and frequency. Formal evaluation
includes cystoscopy, upper tract imaging, cytology, and urine culture. There is no agreed upon screening
guideline for bladder cancer between the American Urological Association (AUA) and USPSTF. Primary care
providers bear the burden of making the decision when to refer and when to treat in the primary setting. Many
bladder cancers are diagnosed later due to the masking symptoms of UTI, especially in women, resulting in a
delayed diagnosis of cancer, and a later stage of cancer limiting treatment options.
Methods: An exhaustive search of online medical literature was performed using MEDLINE-PubMed, Web
of Science, Google Scholar, and CINAHL-EBSCO. Keywords used included: bladder cancer, urinary tract
infection, hematuria, primary care, and gender disparities. Eligible studies were assessed using the GRADE
criteria.
Results: A total of one hundred sixty seven articles were reviewed, eleven articles read in their entirety, and
two articles met inclusion criteria and were analyzed using the GRADE guidelines. Both studies were
retrospective cohort studies and showed that a delay in diagnosis of bladder cancer is concealed by symptoms
resembling urinary tract infections, especially in women. The overall quality of the studies is very low due to
observational studies. Further studies need to be conducted to improve quality of evidence in regards to the
effects of delayed diagnosis and laxity in following guidelines.
Conclusion: Delaying referral and formal evaluation for the source of urinary tract infections and hematuria
in the primary care setting is delaying the diagnosis of bladder cancer, especially in women. Strict adherence to
the AUA guidelines needs to be followed for referral and evaluation for the source of the irritative symptoms.
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Abstract   
 
Background: Bladder cancer is the seventh-leading cause of cancer-related deaths in the US. 
Presenting signs include hematuria and irritative voiding symptoms including dysuria and 
frequency. Formal evaluation includes cystoscopy, upper tract imaging, cytology, and urine 
culture. There is no agreed upon screening guideline for bladder cancer between the American 
Urological Association (AUA) and USPSTF. Primary care providers bear the burden of making 
the decision when to refer and when to treat in the primary setting. Many bladder cancers are 
diagnosed later due to the masking symptoms of UTI, especially in women, resulting in a 
delayed diagnosis of cancer, and a later stage of cancer limiting treatment options.  
 
Methods: An exhaustive search of online medical literature was performed using MEDLINE-
PubMed, Web of Science, Google Scholar, and CINAHL-EBSCO. Keywords used included: 
bladder cancer, urinary tract infection, hematuria, primary care, and gender disparities. Eligible 
studies were assessed using the GRADE criteria. 
 
Results:  A total of one hundred sixty seven articles were reviewed, eleven articles read in their 
entirety, and two articles met inclusion criteria and were analyzed using the GRADE guidelines. 
Both studies were retrospective cohort studies and showed that a delay in diagnosis of bladder 
cancer is concealed by symptoms resembling urinary tract infections, especially in women. The 
overall quality of the studies is very low due to observational studies. Further studies need to be 
conducted to improve quality of evidence in regards to the effects of delayed diagnosis and laxity 
in following guidelines. 
 
 
Conclusion:  Delaying referral and formal evaluation for the source of urinary tract infections 
and hematuria in the primary care setting is delaying the diagnosis of bladder cancer, especially 
in women. Strict adherence to the AUA guidelines needs to be followed for referral and 
evaluation for the source of the irritative symptoms.  
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Higher Rates of Undiagnosed Bladder Cancer in Women Due to Misdiagnosis as Urinary 
Tract Infection  
Background 
 
 Bladder cancer is the fourth most commonly diagnosed cancer in men, ninth in women, 
and the seventh-leading cause of cancer-related deaths. 1 Approximately 71 000 cases were 
diagnosed in 2009. “Approximately 14 330 people died of the disease (10 180 men and 4150 
women). One fourth of all cases of bladder cancer and 20% to 40% of all invasive tumors have 
already metastasized to the lymph nodes at the time of diagnosis.” 2 The question arises as to 
why this cancer has metastasized to the nodes by the time of diagnosis. There is no agreed 
screening for bladder cancer among the various disciplines in medicine. It is diagnosed typically 
upon presentation of irritative voiding symptoms or hematuria. Irritative voiding symptoms 
include urgency, frequency, and dysuria.  These symptoms mimic those of a urinary tract 
infection. Hematuria is either gross or microscopic and is typically discovered incidentally. 
 Microhematuria can be discovered on a urine dip-stick during a primary care screening 
leading the primary care provider (PCP) to treat empirically as a urinary tract infection, or 
sending the urine for culture and sensitivity for further diagnostic evaluation. Many patients 
presenting with microscopic hematuria in the primary care setting are not evaluated fully 
according to American Urological Association (AUA) guideline. 3 According to the Elias et al 
study4, “subjects at high risk for bladder cancer based on greater than 10 years of smoking or 
environmental exposure with microscopic hematuria are rarely evaluated thoroughly and only 
12.8% were referred for urologic evaluation.” With this low percentage for formal evaluation, 
many cases of bladder cancer are missed or diagnosed later resulting in a higher stage of bladder 
cancer at time of diagnosis and higher mortality rates due to this delay.  
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The AUA defines asymptomatic microhematuria (AMH) as “three or greater red blood 
cells (RBC) per high powered field (HPF) on a properly collected urinary specimen in the 
absence of an obvious benign cause. A positive dipstick does not define AMH, and evaluation 
should be based solely on findings from microscopic examination of urinary sediment and not on 
a dipstick reading. A positive dipstick reading merits microscopic examination to confirm or 
refute the diagnosis of AMH.” 3 The gold standard, according to the AUA, for microhematuria 
evaluation includes a cystoscopy, upper tract imaging (such as a CT urogram), and cytology. 
Urine cultures are typically sent to rule out a urinary tract infection. 3 The cystoscopy is a direct 
visualization of the bladder using a camera that is inserted through the urethra into the bladder. 
This allows for bladder wall sampling with a biopsy if there are any lesions or suspicious regions 
warranting further evaluation. A CT urogram is a CT scan performed with and without IV 
contrast examining the kidneys and ureters for potential source for the hematuria or even 
discovery of a mass in the upper tract. A urine cytology should include either an NMP-22 or a 
bladder wash/first morning void for cytology investigating for atypical or cancer cells in the 
urine. A urine culture would be sent to rule out urinary tract infections.  
There is always risk with any procedure and potential of incidental findings on 
diagnostics requiring further evaluation. Cystoscopy can introduce bacteria or further the 
hematuria; it can even puncture the bladder wall if not performed by a licensed provider trained 
in urologic procedures. CT scans expose patients to potentially unnecessary radiation and the 
expense of the image study could be more than people can afford or wish to prioritize as an 
expense in their budget. CT scans may also reveal an additional pathology not associated with 
the hematuria requiring further evaluation or specialty referral. Urine cytologies and cultures are 
non-invasive labs; however, they have a financial cost, as well as the possibility of a false-
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positive or false-negative or reveal an incidental finding of a potentially benign pathology that 
requires even further diagnostic evaluation, creating even more of a financial burden. The line is 
fine as to when to delve into diagnostics and when to treat the patient and not the labs.  
 Urinary tract infections (UTIs) may present with microhematuria, gross hematuria, 
urgency, frequency, and dysuria.  The gold standard for urinary tract infection diagnosis includes 
a culture and sensitivity. Many PCP treat UTIs empirically, meaning treating with antibiotics 
before a culture has returned with definitive growth or no growth in the urine. This is routinely 
seen in the PCP setting for patient comfort to treat them as quickly as possible due to the 
discomfort experienced during a UTI. Women are treated on an average of three courses of 
antibiotics before referral to urology for formal evaluation. They are typically referred for 
recurrent urinary tract infection and not hematuria. The AUA best practice policy states that 
“patients at high-risk for bladder cancer (especially those with a history of smoking or chemical 
exposure) should be considered for a full urologic evaluation after 1 properly performed 
urinalysis documenting the presence of at least 3 RBC per HPF.” 3 The lack of referral to urology 
for a complete evaluation is not performed routinely and uniformly in most PCP settings.   
 Urinary tract infections or irritative voiding symptoms such as dysuria or frequency could 
be presenting signs of a bladder tumor masking the underlying diagnosis that could be a 
symptomatic bladder cancer (BCa). Furthermore, “men with hematuria are 65% more likely to 
receive urological referral compared with women, who are more likely to be treated for UTI or 
referred for gynecological evaluation.” 5 Women are typically treated as having a benign 
pathology when compared to men presenting with hematuria or irritative voiding symptoms; this 
could lead to a later diagnosis of BCa in women when compared to men. Many of these cases 
 11 
involved in research do not include CIS bladder cancer. CIS can lead to high-grade cancer if not 
treated.  
 Treatment for bladder cancer includes intra-vesicle chemotherapy instillations (eg, 
valrubicin, BCG, and/or mitomycin), radiation, and surgery (including tumor resections and 
cystectomy). Many of the low-grade bladder cancers can be eradicated with in-office 
cystoscopies using fulguration or simple extraction with clamshell biopsy. Surveillance protocol 
is initiated and outcomes for recurrence are low. However, if the diagnosis is delayed, the 
treatment options change drastically to more invasive treatments and potentially, non-treatable. 
The prompt referral to urology is imperative so diagnosis can be made sooner with hopes of 
better outcomes and lower mortality rates. A simple UTI may not be so simple. The question is, 
could untreated bladder cancer in women be higher due to its misdiagnosis as urinary tract 
infection in the primary care setting? 
 
Methods  
 Exhaustive search of available medical literature using the following search engines: 
MEDLINE (PubMed), CINAHL, Web of Science, and Google Scholar. Key terms searched 
included hematuria, urinary tract infection, bladder cancer, bladder neoplasms, and gender 
disparities. Eligible criteria included studies that compared men and women, used urinary tract 
infection as the presenting symptom, had a final diagnosis of bladder cancer, and were published 
in English utilizing human participants.  All studies were analyzed using the GRADE criteria. 6  
 
Results 
 The search resulted in a total of 167 articles that were reviewed.  Eleven articles read in 
their entirety. After applying the eligibility criteria, two articles remained. 7, 8 (See Table 1)  
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Richards et al 
 
 The Richards et al study7 examines gender disparities and delay in diagnosis of bladder 
cancer due to presenting symptoms similar to urinary tract infection. This is a retrospective 
cohort study of  39 211 patients with qualifying inclusion criteria, 12 195 were Medicare 
enrollees with 23% women, 90% Caucasian. Subjects chosen were at least sixty-six years old or 
older, enrolled in Medicare, and were registered in Surveillance, Epidemiology and End Results 
(SEER) between 2007 and 2009. Hematuria was the primary presenting symptom in this study. 
Hematuria of one year or less from other sources including kidney stones, actual infection, 
pyelonephritis, or other non-specific etiologies was excluded. More women than men presented 
with hematuria with 81.4% compared to 60.5% respectively. This study determined the mean 
time from hematuria or UTI claim to BCa diagnosis was 72.2 days for women and 58.9 days for 
men. Time to diagnosis of 2-3 months, 6 months, and 6-12 months increased the odds of at least 
a grade of pathology T2 (see Table 2) compared with time to diagnosis less than 30 days. 
Women were more likely than men to have at least one urine culture on file and be treated 
empirically with antibiotics. There is a greater likelihood of men and women presenting with 
UTI symptoms than presenting only with hematuria. There was no association between time to 
diagnosis and node positivity regardless of sex. 7 Refer to Tables 3 and 4 for further information 
and data.  
Cohn et al 
 
  The Cohn et al study8 addressed potential reasons why women have a disproportionately 
higher mortality rate after diagnosis of bladder cancer. This is a retrospective population-based 
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study looking at timing of presentation (UTI or hematuria) to diagnosis. This study also 
examines the date of presentation to the final diagnosis of bladder cancer by gender. This study 
consisted of  7 649 participants, 5 416 men and 2 233 women. The mean age of men was 55.7 
(+/- 7.8 years), women 57.0 (+/-7.2 years). The average timing from presentation of hematuria to 
diagnosis of bladder cancer for men was 73.6 days and 85.4 days for women. Women were 
diagnosed more than men with UTI with an odds ration (OR) of 2.32 (95% CI 2.07-2.59). 
Women were less likely than men to have a formal evaluation with upper tract imaging with an 
OR of 0.80 (CI 95% 0.71-0.89). Women had a greater prevalence of a microscopic hematuria 
diagnosis than men with 1.39 (CI 95% +/- 1.61) with men 1.19 (+/- 1.35). Women had greater 
incidence of urine culture with 0.83 (+/- 1.20) compared to men 0.53 (+/- 0.86). Finally, women 
had a higher incidence of greater than three courses of antibiotics compared to men 33.1% to 
17.6%, respectively. More men had upper tract imaging that women with 77.3% of men and 
73.1% women receiving imaging. Those with a diagnosis of UTI had an associated delay of 27.9 
days (CI 95% 23.0-32.7). See Tables 5 and 6 for further data. 8  
 
Discussion  
 Could untreated bladder cancer in women be higher due to its misdiagnosis as urinary 
tract infection in the primary care setting? In the presentation at the AUA in July 2015 by KA 
Richards, the author claimed delayed diagnosis is an issue due to misdiagnosis. 9 The irritative 
symptoms that could be caused by a tumor can easily be mistaken for a UTI. However, at what 
point are primary care providers delaying the referral due to potential inconvenience of 
conflicting schedules and insurance prior authorities? At what point are primary care providers 
hesitating on sending labs to rule in or rule out a diagnosis instead of treating assumed infections 
empirically with antibiotics? Are primary care providers delaying ordering an upper tract study 
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to investigate a potential source for hematuria? Primary care providers are in a difficult situation 
of making the “correct” diagnosis and decision to refer out or to treat in office. A simple UTI is 
just that, simple. The implications for missing a more severe diagnosis are profound though. By 
following the guidelines the provider could prevent the later diagnosis of high-grade bladder 
cancer (>T2). 
UTI symptomatology is similar enough to that of a bladder tumor and can be masking the 
diagnosis of bladder cancer. The masking of the symptoms greatly delays the referral to specialty 
for further evaluation. The Richards’ et al study7 is the first to address UTI signs and symptoms 
as the presenting factor to bladder cancer, specifically evaluating how gender disparities impact 
the time of diagnosis to success in treatment. A delay by only 40 days can deeply impact the 
outcomes negatively. Moreover, this study found that women presenting with T1 died relatively 
sooner than men with UTI and patients presenting with hematuria regardless of sex for bladder 
cancer specific and all cause survival. 7 The Cohn et al study8 determined that women had a two 
week delay in diagnosis when compared to men and a 15% delay from presentation to diagnosis 
in the 6 month interval, and a 25% delay in 9 months and greater intervals. “While most patients 
have non-invasive urothelial cell carcinoma at diagnosis, up to 50% will have high grade 
disease.” 8 Cohn et al study did include reference to in situ carcinoma stating that patients should 
have a cytology performed at the minimum for irritative symptoms, persistent microhematuria, 
tobacco use, and chemical exposure. All of these findings greatly emphasize the importance of 
following the bladder cancer guidelines to evaluate for potential malignancies, specifically in 
women.  
Is there a right answer or guideline to follow regarding referral and treatment? There is 
constant discourse between the USPSTF and the specialty guidelines, such as the American 
 15 
Cancer Association and American Urological Association. The USPSTF is not aggressive in 
screening and diagnostics for bladder cancer; whereas the ACA and AUA have a lower threshold 
for formal evaluation. If primary care providers had a lower threshold for referral, bladder cancer 
could be diagnosed sooner and there would be more treatment options for patients. Guidelines 
need to be followed more stringently and should have greater follow-through with referrals and 
diagnostics. Diagnosing bladder cancer earlier will offer more treatment options in the earlier 
stages of bladder cancer, lowering mortality rates in women. Primary care providers need to have 
a lower threshold for investigating the source of infection and hematuria, discussing the 
implications with their patients, and including the patients in the decision for diagnostics or 
empirical treatment. Avoiding the differential diagnosis of bladder cancer in lieu of the easier 
diagnosis of infection or irritative voiding is not serving patients in their best interest and limits 
future treatment options and ultimately mortality. 
 The limitations of the Richards’ et al study7 address potential coding errors of UTI signs 
and symptoms, hematuria, microhematuria, and irritative signs and symptoms that could be 
concealing a tumor. Only insured patients were accounted for and must be enrolled in SEER with 
a bladder cancer diagnosis and hematuria or UTI as presenting symptom; self-pay patients and 
those that were not enrolled in SEER were not counted for in the studies. Smoking, family 
history, and chemical exposure were not fully addressed in the studies. Age range included 66 
and older; younger patients were excluded.  Studies did not evaluate for in situ, which could 
become high-grade transitional cell carcinoma (TCC) if left untreated.  
 Limitations of the Cohn et al study8 included only privately insured patients and not those 
on Medicare or uninsured. This eliminates a large majority of greater than 65 year olds that are at 
higher risk for UTI and bladder cancer and also under represents those that are uninsured. There 
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was an assumption that those that are younger would represent the older population, as well. 
Bladder cancer tends to present later in life and is not common in those under 65 years. A larger 
cohort study is required to encompass a broader spectrum of patients presenting with UTI, 
hematuria, or irritative symptoms. “Women ultimately diagnosed with bladder cancer were 2.29 
(95% CI 1.97-2.67) times as likely to undergo three or more primary care visits for hematuria 
prior to urologic referral.” 10 Cohn et al study8 claims that UTI was the single most dominant 
predictor delaying the final diagnosis of bladder cancer and that only a fraction of primary 
providers referred to urology for further evaluation.  
Future studies need to be conducted for validation. Studies including in situ carcinoma, 
broader age spectrum, privately insured and non-insured patients, and social factors need to be 
addressed. Future research would emphasize the importance of early detection of bladder cancer 
and not ignoring the easy diagnosis of a bladder infection or irritative symptoms of no etiology. 
Using the Richards et al and Cohn et al studies7, 8 as a foundation for further research will 
hopefully decrease the mortality rates due to bladder cancer by establishing guidelines for earlier 
referral and earlier detection.  
Conclusion  
 Urinary tract infection in women and men can conceal the underlying etiology of bladder 
cancer. Understandably, not everyone with a UTI is referred to urology for a formal evaluation; 
however, it is important to not ignore the signs and symptoms of something potentially much 
more dangerous and with an insidious onset. Perhaps women are more likely to ignore the 
underlying cause of the UTI and simply live with the diagnosis of bacterial infection or irritated 
bladder without considering a more serious diagnosis of bladder cancer whereas men are not as 
tolerant of UTI or hematuria and press for referral to urology. Perhaps providers are more likely 
 17 
to use the diagnosis of UTI in women and push for referral for men due to the lower threshold 
for infection in men. There are many reasons and rationales as to why women are not referred as 
quickly for formal evaluation as men. This needs to be pursued further even though the reasons 
may have bias in clinical judgment and reasoning. The findings from the studies reviewed 
established that there is a delay in diagnosis of bladder cancer in women relating to cancer 
symptoms being mistaken as UTIs. Therefore, close adherence to the AUA guidelines is strongly 
recommended.  
 
Keywords:  Bladder cancer, urinary tract infection, hematuria, primary care, gender disparities 
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Tables 
Table 1. Grade Table for Eligible Studies 
 
Study Design Downgrade Criteria Upgrade 
Criteria Limitations Indirectness Inconsistency Imprecision Publication 
bias 
Richards et 
al7  
Cohort, 
Observational 
Seriousa,b Not Serious Not Serious Not Serious Not Serious No 
Cohn et al8 Cohort, 
Observational 
Seriousb,c Not Serious Not Serious Not Serious Not Serious No 
a Excluded younger at risk participants and only included Medicare 
b Lack accounting of social factors which could be confounders 
c Excluder older at risk participants and only included private insurances 
 
 
 
Table 2. Bladder Cancer Stages1 
Stage Description 
Stage 0a (Ta, N0, M0) Non-invasive papillary carcinoma, No nodes, No distant sites 
Stage 0is (Tis, N0, M0) Non-invasive, flat carcinoma (Tis) or carcinoma in situ (CIS). 
Growth in the inner lining layers of the bladder. No nodes, no 
distant sites 
Stage I (T1, N0, M0) 
Growth into the layer of connective tissue under the lining. No 
nodes, no distant sites 
Stage II (T2, N0, M0) 
Growth into the thick muscle layer of the bladder, but not 
through the layer into the fatty tissue surrounding the bladder 
(T2 is fatty tissue invasive). No nodes, or distant sites 
Stage III (T3, N0, M0) 
Growth through the muscle layer through the fatty tissue 
surrounding the bladder. Potentially spreading to the prostate, 
uterus, or vagina. No nodes, or distant sites 
Stage IV (T4, N0, M0) 
 
T4b N0, M0: Cancer has grown through the bladder wall and 
into the pelvic or abdominal wall. 
 
Stage IV (T4, N1-3, M0) 
Any T, N1 to N3, M0: cancer has spread to nearby lymph 
nodes (N1-N3) but not to distant sites (M0) 
Stage IV (T, N, M1) 
Any T, Any N, M1: Cancer has spread to distant lymph nodes 
or to sites such as bones, liver, or lungs 
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Table 3. Baseline patient characteristics and assessment of clinical course from 
initial symptom presentation to diagnosis with bladder cancer7 
 Men (n = 9326) Women (n = 2869) P-value 
Mean age, years (95% CI) 76.6 (76.4–76.8) 78.2 (77.9–78.5) <0.0001 
Days from symptoms to bladder cancer diagnosis, mean (95% CI) 58.9 (57.3–60.5) 72.2 (69.0–75.4) <0.0001 
Time to diagnosis, % (n)   <0.0001 
≤1 month 53.6 (5004) 45.9 (1317)  
2–3 months 26.7 (2488) 28.0 (804)  
3–6 months 9.6 (896) 12.7 (364)  
6–12 months 10.1 (938) 13.4 (384)  
Race/ethnicity, % (n)   <0.0001 
White 91.3 (8514) 89.0 (2552)  
Black 4.0 (373) 6.0 (172)  
Hispanic 1.1 (103) 1.6 (45)  
Other 3.6 (336) 3.5 (100)  
Initial diagnosis was hematuria, % (n) 81.4 (7591) 60.5 (1736) <0.0001 
Year of initial diagnosis, % (n)   0.15 
2007 37.2 (3470) 37.5 (1076)  
2008 35.7 (3329) 37.1 (1064)  
2009 27.1 (2527) 25.4 (729)  
Metropolitan statistical area (census 2000), % (n)   0.004 
Lives in MSA 82.1 (7657) 84.4 (2421)  
Does not live in MSA 17.9 (1669) 15.6 (448)  
Charlson Co-morbidity Index, % (n)   <0.0001 
0 56.0 (5222) 62.2 (1784)  
1 26.4 (2462) 24.2 (694)  
2 10.3 (961) 8.7 (250)  
≥3 7.3 (681) 4.9 (141)  
Infectious work-up    
Urine culture sent, mean (CI) 0.83 (0.81–0.85) 1.32 (1.27–1.37) <0.0001 
Antibiotic prescribed, % (n) 23.4 (2184) 35.5 (1018) <0.0001 
Malignant work-up    
Any abdominal/pelvic imaging, % (n) 76.8 (7166) 79.4 (2279) 0.004 
Urine cytology sent, % (n) 38.0 (3540) 39.2 (1124) 0.21 
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Table 4. Bladder-cancer specific mortality rates7 
 Bladder-cancer specific 
mortality 
Overall mortality    
HR 95% CI P-Value HR 95% CI P-Value  
Also controlled for tumor stage, age, race, CCI, number of hematuria claims and census tract-level income. 
Women       
Presenting symptom      
Hematuria Ref Ref  Ref Ref  
UTI 1.37 (1.10–1.71) 0.005 1.47 (1.28–1.69) <0.0001 
Time to diagnosis      
<30 days Ref Ref  Ref Ref  
2–3 months 0.85 (0.67–1.09) 0.21 0.81 (0.70–0.95) 0.008 
3–6 months 0.91 (0.67–1.24) 0.55 0.82 (0.67–1.00) 0.06 
6–12 months 0.98 (0.71–1.34) 0.88 1.03 (0.85–1.25) 0.76 
Men       
Presenting symptom      
Hematuria Ref Ref  Ref Ref  
UTI 1.5 (1.28–1.77) <0.0001 1.39 (1.28–1.52) <0.0001 
Time to diagnosis      
<30 days Ref Ref  Ref Ref  
2–3 months 0.85 (0.72–1.00) 0.05 0.88 (0.81–0.96) 0.003 
3–6 months 0.92 (0.72–1.16) 0.47 1.12 (0.99–1.26) 0.07 
6–12 months 0.89 (0.70–1.13) 0.34 1.1 (0.97–1.24) 0.13 
 
 
 
Table 5. Baseline patient characteristics8 
 Men 
(N=5416) 
Women 
(N=2233) 
P-value 
Age, years (95% CI) 57.0 (56.8–57.2) 55.7 (55.4–56.1) <0.001 
Charlson Comorbidity Index score (95% CI) 0.52 (0.50–0.55) 0.46 (0.43–0.50) 0.004 
From metropolitan statistical area 81.5% 83.9% 0.01 
Number of hematuria visits (95% CI) 2.74 (2.70–2.79) 2.74 (2.67–2.81) 0.46 
Hematuria ICD-9 code    
  Hematuria unspecified 85.8% 85.1% 0.41 
  Gross hematuria 9.2% 7.5% 0.02 
  Microscopic hematuria 5.0% 7.4% <0.001 
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Table 6. Assessment of clinical course from initial hematuria presentation to 
diagnosis with bladder cancer8 
 Men Women P-value 
Delay in diagnosis of bladder cancer from presentation with hematuria    
Mean no. days from hematuria presentation to bladder cancer diagnosis (95% 
CI) 
73.6 (71.2–76.1) 85.4 (81.3–89.4) <0.001 
Median no. days from hematuria presentation to bladder cancer diagnosis (IQR) 35 (15, 88.5) 41 (17, 117) <0.001 
  Delay < 3 months, n (%) 4068 (75.1) 1538 (68.9) <0.001 
  Delay 3 to 6 months, n (%) 583 (10.8) 308 (13.8)  
  Delay 6 to 9 months, n (%) 379 (7.0) 177 (7.9)  
  Delay 9 to 12 months, n (%) 386 (7.1) 210 (9.4)  
Infectious work-up    
Urinalysis sent 65.8% 67.8% 0.11 
  Mean no. of urinalyses sent (95% CI) 1.19 (1.16–1.45) 1.39 (1.16–1.23) <0.001 
Urine culture sent 38.5% 49.8% <0.001 
  Mean no. of urine cultures sent (95% CI) 0.53 (0.51–0.55) 0.83 (0.78–0.88) <0.001 
UTI claim present 17.6% 33.1% <0.001 
Any antibiotic filled 35.4% 40.1% <0.001 
Malignant work-up    
Any abdominal/pelvic imaging 77.3% 73.1% <0.001 
Cytology sent 36.0% 39.0% 0.01 
 
